--- title: "Steris | 8-K: FY2026 Q4 Revenue Misses Estimate at USD 1.588 B" type: "News" locale: "en" url: "https://longbridge.com/en/news/285993673.md" datetime: "2026-05-11T20:38:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285993673.md) - [en](https://longbridge.com/en/news/285993673.md) - [zh-HK](https://longbridge.com/zh-HK/news/285993673.md) --- # Steris | 8-K: FY2026 Q4 Revenue Misses Estimate at USD 1.588 B Revenue: As of FY2026 Q4, the actual value is USD 1.588 B, missing the estimate of USD 1.596 B. EPS: As of FY2026 Q4, the actual value is USD 2.24, missing the estimate of USD 2.3533. EBIT: As of FY2026 Q4, the actual value is USD 335.2 M. ### Full Year Fiscal 2026 Financial and Operational Metrics #### Revenue Total revenue from continuing operations for STERIS plc increased by 9% to $5.9 billion in fiscal 2026, compared to $5.5 billion in fiscal 2025. Constant currency organic revenue growth from continuing operations was 7% for fiscal 2026. Total Recurring Revenue was $4,684.2 million in fiscal 2026, up from $4,273.8 million in fiscal 2025. Capital Equipment Revenue was $1,251.7 million in fiscal 2026, compared to $1,185.7 million in fiscal 2025. Service Revenue reached $2,875.8 million in fiscal 2026, up from $2,587.9 million in fiscal 2025. Consumables Revenue was $1,808.4 million in fiscal 2026, compared to $1,685.9 million in fiscal 2025. #### Net Income As reported net income from continuing operations for fiscal 2026 was $782.3 million, an increase from $610.1 million in fiscal 2025. Adjusted net income for fiscal 2026 was $1.0 billion, compared to $913.2 million in fiscal 2025. #### Gross Profit As reported gross profit was $2,626.5 million in fiscal 2026, up from $2,402.8 million in fiscal 2025. Adjusted gross profit was $2,633.0 million in fiscal 2026, compared to $2,426.0 million in fiscal 2025. #### Income from Operations As reported income from operations was $1,101.8 million in fiscal 2026, compared to $866.6 million in fiscal 2025. Adjusted income from operations was $1,381.9 million in fiscal 2026, compared to $1,267.5 million in fiscal 2025. #### Operating Costs Cost of revenues was $3,309.4 million in fiscal 2026, up from $3,056.8 million in fiscal 2025. Selling, general, and administrative expenses were $1,407.7 million in fiscal 2026, compared to $1,334.3 million in fiscal 2025. Research and development expenses were $112.9 million in fiscal 2026, compared to $107.6 million in fiscal 2025. Total operating expenses were $1,524.7 million in fiscal 2026, down from $1,536.1 million in fiscal 2025. #### Cash Flow Net cash provided by operations for fiscal 2026 was $1.34 billion, compared with $1.15 billion in fiscal 2025. Free cash flow for fiscal 2026 was $982.9 million, up from $787.2 million in the prior year period, primarily driven by improvements in net income. #### Segment Performance (Full Year Fiscal 2026 vs. Fiscal 2025) - **Healthcare Segment:** Revenue was $4,208.6 million in fiscal 2026, compared to $3,878.7 million in fiscal 2025, with constant currency organic revenue growth of 7.6%. Segment Operating Income was $1,036.4 million in fiscal 2026, compared to $971.5 million in fiscal 2025. - **Applied Sterilization Technologies (AST) Segment:** Revenue increased to $1,138.5 million in fiscal 2026, from $1,038.6 million in fiscal 2025, with constant currency organic revenue growth of 6.7%. Segment Operating Income was $524.7 million in fiscal 2026, compared to $465.6 million in fiscal 2025. - **Life Sciences Segment:** Revenue grew to $588.8 million in fiscal 2026, from $542.3 million in fiscal 2025, with constant currency organic revenue growth of 6.7%. Segment Operating Income was $251.0 million in fiscal 2026, compared to $229.4 million in fiscal 2025. #### Other Metrics The Board of Directors approved a new $1 billion share repurchase program to replace the prior authorization. Healthcare Backlog was $392.1 million in FY26 Q4, compared to $369.2 million in FY25 Q4. Life Sciences Backlog was $98.7 million in FY26 Q4, compared to $83.7 million in FY25 Q4. Total Backlog - Continuing Operations was $490.7 million in FY26 Q4, compared to $452.9 million in FY25 Q4. ### Fiscal 2027 Outlook For fiscal 2027, STERIS plc anticipates as reported revenue to increase by 7-8%, with constant currency organic revenue growth projected at 6-7%. Adjusted earnings per diluted share are expected to increase by 9-11% from fiscal 2026. Capital expenditures are estimated at approximately $375 million, and free cash flow is forecasted to be around $850 million. ### Related Stocks - [STE.US](https://longbridge.com/en/quote/STE.US.md) ## Related News & Research - [Steris forecasts 2027 profit above estimates, banks on procedure-driven demand](https://longbridge.com/en/news/286004292.md) - [Steris misses Q4 adjusted profit expectations; sets $1 bln buyback](https://longbridge.com/en/news/285993904.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Stellantis N.V. (STLA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/286607688.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)